ArticleFrontiers in microbiology2018
Fitness Advantage of
Article in Frontiers in microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed.
- Characterization of anAntibiotics (Basel, Switzerland) · 2026Article
- Complete genomic sequencing and characterization of an ESBL-producingmicroPublication biology · 2026Article
- Host-dependent effects ofFrontiers in microbiology · 2026Article
- Transfer and Fitness of ISMicroorganisms · 2025Article
- Comprehensive analysis of Enterobacteriaceae IncX plasmids reveals robust conjugation regulators PrfaH, H-NS, and conjugation-fitness tradeoff.Communications biology · 2025Article
- Genomic diversity of mcr-carrying plasmids and the role of type IV secretion systems in IncI2 plasmids conjugation.Communications biology · 2025Article
- Case Report: Transferable IncX4 plasmid carryingFrontiers in veterinary science · 2025Article
- Article
- Global Variation inAntibiotics (Basel, Switzerland) · 2024Article
- Flavomycin restores colistin susceptibility in multidrug-resistant Gram-negative bacteria.mSystems · 2024Article
- First Report of Colistin-ResistantAntibiotics (Basel, Switzerland) · 2024Article
- Low prevalence of mcr-1 in Escherichia coli from food-producing animals and food products in China.BMC veterinary research · 2024Article
- Molecular characterization of theFrontiers in veterinary science · 2024Article
- A new variant of the colistin resistance gene MCR-1 with co-resistance to β-lactam antibiotics reveals a potential novel antimicrobial peptide.PLoS biology · 2023Article
- Dissemination of IncI plasmid encodingAntimicrobial agents and chemotherapy · 2023Article
- First Report and Characterization of theMicroorganisms · 2023Article
- Mobile Colistin Resistance (Antibiotics (Basel, Switzerland) · 2023Review
- Prevalence and Genomic Characteristics ofMicrobiology spectrum · 2023Article
- Comparative genomic analysis of Colistin resistant Escherichia coli isolated from pigs, a human and wastewater on colistin withdrawn pig farm.Scientific reports · 2023Article
- Identification ofAntibiotics (Basel, Switzerland) · 2023Article
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this study was to assess the impact of diverse plasmids bearing colistin resistance gene
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.